But I believe CYP doesn't require 3D manufacturing like bone marrow derived technologies, because of the IPSC starting material, which is uniform, consistent and infinitely expandable without facing the issues of cell senescence. I believe 3D is required for bone marrow derived cells because of the senescence issues related to batch to batch inconsistencies?
CYP surpasses the need for 3D cell scaffolding, does it not?
Please correct me if I'm wrong.
Ann: Quarterly Activity Report & Appendix 4C, page-15
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.74M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 22.0¢ | $29.06K | 131.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 951 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.59pm 08/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |